Acquisition attempts
In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. However, Teva prevailed in this acquisition with a substantially higher bid. Bankruptcy
In 2022, Endos stock fell below $1 as the company faced restructuring of its $8 billion of debt. On August 17, 2022 Endo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors. Opioids
Endo is one of the companies named in lawsuits by the states of Ohio, Missouri and Mississippi as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the companys US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.On June 8, 2017, the U.S. Food and Drug Administration (FDA) released a press statement in which it announced that it requested Endo to withdraw its opioid drug, oxymorphone hydrochloride (Opana ER), from the market. Opana has been linked to outbreaks of HIV, hepatitis C and serious blood disorders. It was the first time that the FDA had "taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. "In 2021, New York Attorney General Letitia James filed a lawsuit against Endo and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. See also
Opioid epidemic
Corporate tax inversions
Ireland as a tax haven

References
External links
Official website
Cytokine receptor-like factor 1 is a protein that in humans is encoded by the CRLF1 gene. Function
This gene encodes a member of the cytokine type I receptor family. The protein forms a secreted complex with cardiotrophin-like cytokine factor 1 and acts on cells expressing ciliary neurotrophic factor receptors. The complex can promote survival of neuronal cells. Clinical significance
Mutations in this gene are associated with two conditions, both rare:

Cold-induced sweating syndrome, characterized by profuse hyperhidrosis in cold environmental temperature and characteristic craniofacial and skeletal features)
Crisponi syndrome (CS), characterized by neonatal-onset paroxysmal muscular contractions, abnormal function of the autonomic nervous system and craniofacial and skeletal manifestations such as thick and arched eyebrows, a short nose with anteverted nostrils, full cheeks, an inverted upper lip and a small mouth.It is unknown whether the two conditions are distinct clinical entities or a single clinical entity with variable expressions. Other characteristic features in CRLF1 mutation include marfanoid habitus with progressive kyphoscoliosis and craniofacial characteristics including dolichocephaly, a slender face with poor expression, a nose with hypoplastic nares, malar hypoplasia and prognathism. References
Further reading
External links
GeneReviews/NCBI/NIH/UW entry on Cold-Induced Sweating Syndrome including Crisponi Syndrome
OMIM enries on Cold-Induced Sweating Syndrome including Crisponi Syndrome
Human CRLF1 genome location and CRLF1 gene details page  in the UCSC Genome Browser.This article incorporates text from the United States National Library of Medicine, which is in the public domain.